MedTrace Logo

Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

NCT00134745 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2013-06-14

No results posted yet for this study

Summary

The purpose of this study is to examine whether a larger dosage of estrogen than the one used today will secure the development of a normal sized uterus and increase the strength of the bones in girls and young women with Turner syndrome.

The purpose is also to evaluate whether aortic dilatation is present in this group of patients, and if the estrogen dosage will influence the emotional well-being and self-esteem of the patients.

Conditions

  • Turner Syndrome

Interventions

DRUG

estradiol

tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • The County of Frederiksborg

    collaborator UNKNOWN

  • The foundation of Kaptajnløjtnant Harald Jensen and Wife

    collaborator UNKNOWN

  • The foundation of Mrs. Olga Bryde

    collaborator UNKNOWN

  • The foundation of Mr. Ivan Nielsen

    collaborator UNKNOWN

  • Line Cleemann

    lead OTHER

Principal Investigators

  • Line Cleemann, Doctor · Pediatric Unit, Hillerod Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00134745 on ClinicalTrials.gov